Report Summary
The global Pemetrexed market is valued at million US$ in 2020 and will reach million US$ by the end of 2027, growing at a CAGR of during 2021-2027. The objectives of this study are to define, segment, and project the size of the Pemetrexed market based on company, product type, end user and key regions.
This report studies the global market size of Pemetrexed in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pemetrexed in these regions.
This research report categorizes the global Pemetrexed market by top players/brands, region, type and end user. This report also studies the global Pemetrexed market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Eli Lilly
Abbott Healthcare
Cadila Healthcare
Market size by Product
100mg
500mg
Market size by End User
Pleural Mesothelioma
Non-small Cell Lung Cancer
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Pemetrexed market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2020, and forecast to 2027.
To understand the structure of Pemetrexed market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pemetrexed companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pemetrexed submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Pemetrexed are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
This report includes the estimation of market size for value (million US$) and volume (Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pemetrexed market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Pemetrexed Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Pemetrexed Market Size Growth Rate by Product
1.4.2 100mg
1.4.3 500mg
1.5 Market by End User
1.5.1 Global Pemetrexed Market Size Growth Rate by End User
1.5.2 Pleural Mesothelioma
1.5.3 Non-small Cell Lung Cancer
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Pemetrexed Market Size
2.1.1 Global Pemetrexed Revenue 2017-2027
2.1.2 Global Pemetrexed Sales 2017-2027
2.2 Pemetrexed Growth Rate by Regions
2.2.1 Global Pemetrexed Sales by Regions
2.2.2 Global Pemetrexed Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Pemetrexed Sales by Manufacturers
3.1.1 Pemetrexed Sales by Manufacturers
3.1.2 Pemetrexed Sales Market Share by Manufacturers
3.1.3 Global Pemetrexed Market Concentration Ratio (CR5 and HHI)
3.2 Pemetrexed Revenue by Manufacturers
3.2.1 Pemetrexed Revenue by Manufacturers (2017-2020)
3.2.2 Pemetrexed Revenue Share by Manufacturers (2017-2020)
3.3 Pemetrexed Price by Manufacturers
3.4 Pemetrexed Manufacturing Base Distribution, Product Types
3.4.1 Pemetrexed Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Pemetrexed Product Type
3.4.3 Date of International Manufacturers Enter into Pemetrexed Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Pemetrexed Sales by Product
4.2 Global Pemetrexed Revenue by Product
4.3 Pemetrexed Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Pemetrexed Breakdown Data by End User
6 North America
6.1 North America Pemetrexed by Countries
6.1.1 North America Pemetrexed Sales by Countries
6.1.2 North America Pemetrexed Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Pemetrexed by Product
6.3 North America Pemetrexed by End User
7 Europe
7.1 Europe Pemetrexed by Countries
7.1.1 Europe Pemetrexed Sales by Countries
7.1.2 Europe Pemetrexed Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Pemetrexed by Product
7.3 Europe Pemetrexed by End User
8 Asia Pacific
8.1 Asia Pacific Pemetrexed by Countries
8.1.1 Asia Pacific Pemetrexed Sales by Countries
8.1.2 Asia Pacific Pemetrexed Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Pemetrexed by Product
8.3 Asia Pacific Pemetrexed by End User
9 Central & South America
9.1 Central & South America Pemetrexed by Countries
9.1.1 Central & South America Pemetrexed Sales by Countries
9.1.2 Central & South America Pemetrexed Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Pemetrexed by Product
9.3 Central & South America Pemetrexed by End User
10 Middle East and Africa
10.1 Middle East and Africa Pemetrexed by Countries
10.1.1 Middle East and Africa Pemetrexed Sales by Countries
10.1.2 Middle East and Africa Pemetrexed Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Pemetrexed by Product
10.3 Middle East and Africa Pemetrexed by End User
11 Company Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Details
11.1.2 Company Business Overview
11.1.3 Eli Lilly Pemetrexed Sales, Revenue and Gross Margin (2017-2020)
11.1.4 Eli Lilly Pemetrexed Products Offered
11.1.5 Eli Lilly Recent Development
11.2 Abbott Healthcare
11.2.1 Abbott Healthcare Company Details
11.2.2 Company Business Overview
11.2.3 Abbott Healthcare Pemetrexed Sales, Revenue and Gross Margin (2017-2020)
11.2.4 Abbott Healthcare Pemetrexed Products Offered
11.2.5 Abbott Healthcare Recent Development
11.3 Cadila Healthcare
11.3.1 Cadila Healthcare Company Details
11.3.2 Company Business Overview
11.3.3 Cadila Healthcare Pemetrexed Sales, Revenue and Gross Margin (2017-2020)
11.3.4 Cadila Healthcare Pemetrexed Products Offered
11.3.5 Cadila Healthcare Recent Development
12 Future Forecast
12.1 Pemetrexed Market Forecast by Regions
12.1.1 Global Pemetrexed Sales Forecast by Regions 2021-2027
12.1.2 Global Pemetrexed Revenue Forecast by Regions 2021-2027
12.2 Pemetrexed Market Forecast by Product
12.2.1 Global Pemetrexed Sales Forecast by Product 2021-2027
12.2.2 Global Pemetrexed Revenue Forecast by Product 2021-2027
12.3 Pemetrexed Market Forecast by End User
12.4 North America Pemetrexed Forecast
12.5 Europe Pemetrexed Forecast
12.6 Asia Pacific Pemetrexed Forecast
12.7 Central & South America Pemetrexed Forecast
12.8 Middle East and Africa Pemetrexed Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Pemetrexed Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
